Key facts
- It has raised $3.0M; the latest was Later Stage VC ($1.6M) in Jan 2025.
- Notable investors include Enterprise Ireland, SOSV, BIRAC, Venture Center, Indian Department of Science and Technology — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for CyGenica
- ·The full record, as it builds
Funding rounds
No funding rounds for CyGenica are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CyGenica
Developer of a molecular drug delivery device intended to assist in the system to deliver anticancer drugs, antibiotics, and gene editing toolboxes directly into the cells. The company's device crosses the membrane bilayer and delivers functional molecules into the cytoplasm or other cellular organelles, enabling pharmaceutical and biotechnology firms to create new kinds of anti-cancer drugs, which may consist of an increased brand lifecycle within them.
- Sector
- Healthcare
- HQ
- Cork, Ireland
- Founded
- 2016
- Employees
- 6
- Website
- cygenica.com/
- Ownership
- Privately Held (backing)
CyGenica doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CyGenica shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CyGenica in its N-PORT filings yet. We sweep new filings monthly.